JEVTANA cabazitaxel

Drug Class

Microtubule inhibitor

Mechanism

Binds to tubulin and promotes its assembly into microtubules while preventing disassembly, leading to mitotic block and tumor cell apoptosis.

Approved Indication

Metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing regimen (in combination with prednisone), per its FDA approval.

What This Means For Patients

JEVTANA is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2010) — Sources

Pivotal Clinical Evidence

• TROPIC — de Bono et al., Lancet 2010 (NCT00441831) — Sources

Sources

• https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-cabazitaxel-metastatic-castration-resistant-prostate-cancer
• https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201023lbl.pdf